Upsher-Smith announced the launch of Fluphenazine Hydrochloride tablets, USP in 1 mg, 2.5 mg, 5 mg, and 10 mg strengths.
The fluphenazine hydrochloride tablet market had U.S. sales of approximately $30 million for the 12 months ending January 2023, according to IQVIA. Fluphenazine Hydrochloride Tablets are a generic version of the brand product, Prolixin®.